ReviewNature reviews. Nephrology2025
Microbiota and kidney disease: the road ahead.
Abstract readReview
In one paragraph
Review in Nature reviews. Nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of probiotic supplementation on diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in microbiology · 2026Pooled it
- Microbiome alterations and their potential impact on infection risk in chronic kidney disease and end-stage kidney disease: a narrative review.International urology and nephrology · 2026Review
- Marine-Derived Proteins: Individual Variability in Health Effects Across Protein Structure, Host Genetics, and Gut Microbiota.Comprehensive reviews in food science and food safety · 2026Review
- Gut Microbiota Signatures and Ecological Network Alterations Associated with Hemodialysis.Microorganisms · 2026Article
- The effect of dietary fiber based on fermentability and viscosity on the gut microbiome composition in chronic kidney disease: a systematic review of experimental and clinical trials.Research square · 2026Article
- Microbiome-Targeted Modulation in Renal Transplantation.Journal of clinical medicine · 2026Review
- Development and validation of a predictive model for calcium oxalate kidney stone recurrence integrating gut microbiome and clinical features.World journal of urology · 2026Article
- Life-Course Programming of Kidney Disease: Roles of Gut Microbiota Dysbiosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- Ureic clearance granule ameliorates chronic kidney disease by reshaping microbial dysbiosis via modulating bile acid metabolism.Chinese medicine · 2026Article
- Resveratrol and Redox Regulation in Cardiovascular Disease Across the Life Course: Mechanistic and Translational Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Gut-kidney axis: Dysbiosis and renal disease.World journal of nephrology · 2026Review
- The gut as a central hub for multi-organ crosstalk in aging.Cellular and molecular life sciences : CMLS · 2026Review
- Association of Proton Pump Inhibitor Use with Cancer in Patients Undergoing Maintenance Hemodialysis: A Population-Based Cohort Study.Journal of clinical medicine · 2026Article
- Nutritional Modulation of the Gut-Kidney Axis.Nutrients · 2026Review
- Gut-kidney axis in IgA nephropathy: mechanisms linking microbiota dysbiosis to immune dysregulation, Gd-IgA1 generation, and renal injury.Frontiers in immunology · 2026Review
- Gut microbiota and metabolomics reveal the combined effects ofFrontiers in pharmacology · 2026Article
- Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026Review
- Fecal short-chain fatty acids and serum metabolites: the impact of COVID-19 infection on dialysis patients.Frontiers in nutrition · 2026Article
- Microbiota management: a perspective for kidney transplant patients.Frontiers in transplantation · 2026Review
- Gut microbial-derived metabolites: key players in kidney disease and renal fibrosis.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Patricia P BloomDivision of Gastroenterology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA. ppbloom@med.umich.edu.ORCID 0000-0003-3188-7188
Wendy S GarrettDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-5092-0150
Kristina L PennistonUniversity of Wisconsin School of Medicine and Public Health, Department of Urology, Madison, WI, USA.ORCID 0000-0001-6427-018X
Mari-Karoliina H WinklerSchool of Engineering, Civil and Environmental Engineering, University of Washington, Seattle, WA, USA.ORCID 0000-0002-8366-3293
Stanley L HazenCenter for Microbiome and Human Health, Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-7124-6639
Jose AgudeloCenter for Microbiome and Human Health, Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Mangesh SuryavanshiCenter for Microbiome and Human Health, Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-6054-3926
Ahmed BabikerDivision of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0003-0578-4871
Dylan DoddDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Michael A FischbachDepartment of Bioengineering and ChEM-H, Stanford University, Stanford, CA, USA.
Kerwyn Casey HuangDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8043-8138
Curtis HuttenhowerDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Bina JoeDepartment of Physiology and Pharmacology, Center for Hypertension and Precision Medicine, Microbiome Consortium, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Kamyar Kalantar-ZadehDivision of Nephrology, Hypertension and Transplantation, The Lundquist Institute for Biomedical Innovation at Harbour UCLA Medical Center, Torrance, CA, USA.
Rob KnightCenter for Microbiome innovation, University of California San Diego, La Jolla, CA, USA.
Aaron W MillerCenter for Microbiome and Human Health, Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-8342-1449
Hamid RabbDivision of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-4761-1103
Anvesha SrivastavaDivision of Renal Diseases and Hypertension, Department of Medicine, George Washington University School of Medicine, Washington, DC, USA.
W H Wilson TangCenter for Microbiome and Human Health, Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-8335-735X
Peter J TurnbaughChan Zuckerberg Biohub-San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0888-2875
Alan W WalkerMicrobiome, Food Innovation and Food Security Theme, Rowett Institute, University of Aberdeen, Aberdeen, UK.ORCID 0000-0001-5099-8495
Nicola WilckDepartment of Nephrology and Internal Intensive Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0003-3189-5364
Jiaojiao XuDepartment of Physiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-7036-5131
Tao YangDepartment of Physiology and Pharmacology, Center for Hypertension and Precision Medicine, Microbiome Consortium, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Jonathan HimmelfarbDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Matthew R RedinboDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gary D WuDivision of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael H WoodworthDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-6181-4599
A Lenore AckermanDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID 0000-0003-4192-7649
Sebastian WinterDepartment of Internal Medicine, Division of Infectious Diseases, UC Davis, Davis, CA, USA.ORCID 0000-0003-1532-9178
Markus M RinschenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-9252-1342
Hatim A HassanDivision of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.
Annabel BirueteDepartment of Nutrition Science, Purdue University, West Lafayette, IN, USA.ORCID 0000-0003-2549-0539
Amanda H AndersonDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-1454-4282
Jennifer L PluznickDepartment of Physiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. jpluznick@jhmi.edu.ORCID 0000-0003-3621-2665
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MTRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5MCTSA UM1 at the University of Alabama at BirminghamUM1TR004771 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PATRICE DELAFONTAINE, Orlando M Gutierrez · 2024 to 2026
$29.2MContinuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5MCentral Hub for Kidney Precision MedicineU24DK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$21.1MProject 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic diseaseP01HL147823 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Stanley L Hazen · 2019 to 2026
$17.0MGut Flora Metabolism of Dietary Phosphatidylcholine and CVDR01HL103866 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L · 2010 to 2023
$10.8MKPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4MA universal pipeline for functional characterization of the human microbiota at a massive scaleRM1GM135102 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BUIE, CULLEN RICHARD, DEUTSCHBAUER, ADAM M · 2020 to 2024
$7.6MUAB National Coordinating Center for the George M. O'Brien Kidney National Resource CentersU24DK137318 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Amanda Hyre Anderson, Orlando M Gutierrez · 2023 to 2026
$6.8MUrology Centers Program Interactions Core (U24)U24DK127726 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI Kristina L Penniston · 2020 to 2026
$6.3MPredicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7MNCATS NIH HHS K12 TR004415NCATS NIH HHS U2C TR004867NCATS NIH HHS UH3 TR003288NCATS NIH HHS UM1 TR004771NCCIH NIH HHS R01 AT011396NCCIH NIH HHS R61 AT013008NCEZID CDC HHS U54 CK000601NCI NIH HHS R01 CA255116NHLBI NIH HHS P01 HL147823NHLBI NIH HHS R01 HL103866NHLBI NIH HHS R01 HL122593NHLBI NIH HHS R01 HL171401NHLBI NIH HHS R01 HL172805NIAID NIH HHS K23 AI144036NIAID NIH HHS R01 AI118807NIAID NIH HHS R21 AI166263NIAID NIH HHS R21 AI171537NIAID NIH HHS UM1 AI104681NIA NIH HHS R21 AG079357NIA NIH HHS R21 AG081683NIDDK NIH HHS K08 DK118176NIDDK NIH HHS K23 DK138239NIDDK NIH HHS P30 DK050306NIDDK NIH HHS R01 DK107566NIDDK NIH HHS R01 DK114034NIDDK NIH HHS R01 DK121689NIDDK NIH HHS R01 DK123342NIDDK NIH HHS R01 DK125256NIDDK NIH HHS R01 DK130815NIDDK NIH HHS R01 DK132278NIDDK NIH HHS R01 DK133177NIDDK NIH HHS R01 DK137762NIDDK NIH HHS R01 DK138121NIDDK NIH HHS R01 DK138912NIDDK NIH HHS R01 DK139021NIDDK NIH HHS U01 DK099914NIDDK NIH HHS U01 DK099924NIDDK NIH HHS U01 DK133090NIDDK NIH HHS U24 DK060990NIDDK NIH HHS U24 DK114886NIDDK NIH HHS U24 DK127726NIDDK NIH HHS U24 DK137318NIDDK NIH HHS U54 DK137331NIGMS NIH HHS R35 GM142873NIGMS NIH HHS R35 GM152079NIGMS NIH HHS RM1 GM135102
Abstract
More than 850 million individuals worldwide, accounting for 10-15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota - a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease.
Indexed as
Gastrointestinal MicrobiomeKidney DiseasesMicrobiotaRenal Insufficiency, ChronicAcute Kidney InjuryHumans
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.